Comparative Pharmacology
Head-to-head clinical analysis: NATESTO versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATESTO versus TREST.
NATESTO vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to androgen receptors, activating gene transcription for male sexual development and maintenance of secondary sexual characteristics.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
One 10 mg buccal tablet applied twice daily to the gum region above the incisor tooth, approximately 12 hours apart; morning and evening.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
The terminal elimination half-life of testosterone after intramuscular injection of testosterone enanthate is approximately 8 days (range 4–12 days), reflecting slow absorption from the oily depot. This prolonged half-life supports a dosing interval of every 2–4 weeks.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Following intramuscular administration of testosterone enanthate, approximately 90% of the dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (e.g., androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone in urine is negligible (<1%).
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category C
Category C
Androgen
Androgen